ASCO 2022 Breast/Gyn

CME

Key Studies in Breast and Gynecologic Cancers: Independent Conference Coverage of the 2022 ASCO Annual Meeting

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: August 17, 2022

Expiration: August 16, 2023

Joyce O'Shaughnessy
Joyce O'Shaughnessy, MD
Angeles Alvarez Secord
Angeles Alvarez Secord, MD, MHSc

Activity

Progress
1
Course Completed

References

  1. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract LBA3.
  2. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9-20.
  3. Rugo HS, Bardia A, Marmé F, et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract LBA1001.
  4. Wander SA, Han HS, Zangardi ML, et al. Clinical outcomes with abemaciclib after prior CDK4/6 inhibitor progression in breast cancer: a multicenter experience. J Natl Compr Canc Netw. 2021;1-8.
  5. Kalinsky K, Accordino MK, Chiuzan C, et al. A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract LBA1004.
  6. Finn RS, Rugo HS, Dieras VC, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract LBA1003.
  7. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925-1936.
  8. Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379:1926-1936.
  9. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Eng J Med. 2022;386:942-950.
  10. Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021;22:489-498.
  11. Jones RH, Casbard AC, Carucci M, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2020;21:345-357.
  12. Jones RH, Casbard AC, Carucci M, et al. Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor–positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 1005.
  13. Howell SJ, Casbard A, Carucci M, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated PFS, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol. 2022;23:851-864.
  14. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810-821.
  15. Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556-567.
  16. Pembrolizumab prescribing information. Whitehouse Station, NJ: Merck & Co., Inc; 2022.
  17. Pusztai L, Denkert C, O’Shaughnessy J, et al. Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 503.
  18. Sharma P, Stecklein SR, Yoder R, et al. Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT). Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 513.
  19. Whelan TJ, Smith S, Nielsen TO, et al. LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC). Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract LBA501.
  20. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31:2382-2387.
  21. Monk BJ, Parkinson C, Lim MC, et al. ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract LBA5500.
  22. Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. 2017;390:1949-1961.
  23. González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391-2402.
  24. Li N, Zhu J, Yin R, et al: Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME study): A randomized, double-blind, placebo- controlled, phase 3 trial. Presented at: 2022 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; March 19-22, 2022. Abstract 244.
  25. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416-2428.
  26. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495-2505.
  27. Pignata S, Oza A, Hall G, et al. ORZORA: Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status. Presented at: Society of Gynecologic Oncology 52nd Annual Meeting on Women’s Cancer; March 19-25, 2021. Abstract S29.
  28. Pignata S, Oza AM, Hall G, et al. Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 5519.
  29. Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381:2403-2415.
  30. Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014;6:229-239.
  31. Veneris JT, Darcy KM, Mhawech-Fauceglia P, et al. High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol. 2017;146:153-160.
  32. Munster PM Greenstein AE, Fleming GF, et al. Overcoming taxane resistance: pleclinical and phase I studies of relacorilant, a selective glucocorticoid receptor modulator, with nab-paclitaxel in solid tumors. Clin Cancer Res. 2022;Epub ahead of print.
  33. Colombo N, Nguyen DD, Fleming GF, et al. Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves PFS in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study. Presented at: European Society for Medical Oncology Congress 2021; September 17-21, 2021. Abstract 721O.
  34. Colombo N, Van Gorp T, Matulonis UA, et al. Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract LBA5503.
  35. Dostarlimab prescribing information. Philadelphia, PA: GlaxoSmithKline; 2021.
  36. European Medicines Agency. Dostarlimab prescribing information. www.ema.europa.eu/en/medicines/human/EPAR/jemperli. Accessed August 1, 2022.
  37. Crosbie EJ, Kitson SJ, McAlpine JN, et al. Endometrial cancer. Lancet. 2022;399:1412-1428.
  38. Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (pMMR/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer. 2022;10:e003777.
  39. Oaknin A, Pothuri B, Gilbert L, et al. Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or pMMR/MSS) endometrial cancer (EC): The GARNET study. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 5509.
  40. Tewari KS, Sill MW, Long, HJ III, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014; 370:734-743.
  41. Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and AEs analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017;390:1654-1663.
  42. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385:1856-1867.
  43. Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021; 22:609-619.
  44. Tisotumab vedotin prescribing information. Bothell, WA: Seagen Inc.; 2022.
  45. Lorusso D, Vergote I, O’Cearbhaill RE, et al. Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 5507.
  46. Tewari KS, Colombo N, Monk BJ, et al. Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 5506.
  47. US Food and Drug Administration. FDA approves first targeted therapy for HER2-low breast cancer. https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-her2-low-breast-cancer. Accessed August 8, 2022.